Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Kreos
Deal Size : $5.9 million
Deal Type : Financing
Kiadis Announces the Placement of €5 Million Convertible Bonds with Kreos
Details : The conversion of a sizeable portion of Kiadis's loan into a convertible structure supports its recent refocus on its proprietary K-NK platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $5.9 million
October 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Kreos
Deal Size : $5.9 million
Deal Type : Financing
Lead Product(s) : K-NK002
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IND supports the Company’s planned NK-REALM Phase 1/2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 09, 2020
Lead Product(s) : K-NK002
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement
Details : This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $40.0 million
January 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Iniparib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
Details : Iniparib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2010
Lead Product(s) : Iniparib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plerixafor
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Shi, Patricia, M.D.
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Details : Plerixafor is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2010
Lead Product(s) : Plerixafor
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Shi, Patricia, M.D.
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
